Market research
1BT.F Enlivex Therapeutics Ltd
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 23M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.47
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011319527
- Market cap
- 23M
- P/E ratio
- 0.0
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.47
About
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1BT.F discussion.
5 years, 4 months ago
Enlivex Therapeutics Ltd is currently in a long term downtrend where the price is trading 30.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Enlivex Therapeutics Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 11.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 30.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Enlivex Therapeutics Ltd gets an overall score of 2/5.